Journal of Cystic Fibrosis
Volume 11, Issue 1 , Pages 8-13 , January 2012

Chronic Stenotrophomonas maltophilia infection and exacerbation outcomes in cystic fibrosis

  • Valerie Waters

      Affiliations

    • Division of Infectious Diseases, Department of Pediatrics, The Hospital for Sick Children, University of Toronto, 555 University Avenue, Toronto, Canada M5G 1X8
    • Corresponding Author InformationCorresponding author at: Division of Infectious Diseases, The Hospital for Sick Children, 555 University Avenue, Toronto, Ontario, Canada M5G 1X8. Tel.: +1 416 813 7654x4541; fax: +1 416 813 8404.
    • ,
  • Eshetu G. Atenafu

      Affiliations

    • Department of Biostatistics, Princess Margaret Hospital, University Health Network, University of Toronto, 610 University Avenue, Toronto, Canada M5G 2M9
    • ,
  • Juliana Giraldo Salazar

      Affiliations

    • Division of Respiratory Medicine, Department of Pediatrics, The Hospital for Sick Children, University of Toronto, 555 University Avenue, Toronto, Canada M5G 1X8
    • ,
  • Annie Lu

      Affiliations

    • Division of Infectious Diseases, Department of Pediatrics, The Hospital for Sick Children, University of Toronto, 555 University Avenue, Toronto, Canada M5G 1X8
    • ,
  • Yvonne Yau

      Affiliations

    • Division of Microbiology, Department of Pediatric Laboratory Medicine, The Hospital for Sick Children, University of Toronto, 555 University Avenue, Toronto, Canada M5G 1X8
    • ,
  • Larissa Matukas

      Affiliations

    • Division of Microbiology, St. Michael's Hospital, University of Toronto, 30 Bond Street, Toronto, Canada M5B 1W8
    • ,
  • Elizabeth Tullis

      Affiliations

    • Division of Respirology and Keenan Research Centre of Li Ka Shing Knowledge Institute, Department of Medicine, St. Michael's Hospital, University of Toronto, 30 Bond Street, Toronto, Canada M5B 1W8
    • ,
  • Felix Ratjen

      Affiliations

    • Division of Respiratory Medicine, Department of Pediatrics, The Hospital for Sick Children, University of Toronto, 555 University Avenue, Toronto, Canada M5G 1X8

Received 30 May 2011 ,Revised 8 July 2011 ,Accepted 24 July 2011.

References 

  1. Waters V, Yau Y, Prasad S, Lu A, Atenafu E, Crandall I, et al. Stenotrophomonas maltophilia in cystic fibrosis: serologic response and effect on lung disease. Am J Respir Crit Care Med. 2011;183:635–640
  2. Marchac V, Equi A, Le Bihan-Benjamin C, Hodson M, Bush A. Case–control study of Stenotrophomonas maltophilia acquisition in cystic fibrosis patients. Eur Respir J. 2004;23:98–102
  3. Talmaciu I, Varlotta L, Mortensen J, Schidlow DV. Risk factors for emergence of Stenotrophomonas maltophilia in cystic fibrosis. Pediatr Pulmonol. 2000;30:10–15
  4. Graff GR, Burns JL. Factors affecting the incidence of Stenotrophomonas maltophilia isolation in cystic fibrosis. Chest. 2002;121:1754–1760
  5. Denton M, Todd NJ, Kerr KG, Hawkey PM, Littlewood JM. Molecular epidemiology of Stenotrophomonas maltophilia isolated from clinical specimens from patients with cystic fibrosis and associated environmental samples. J Clin Microbiol. 1998;36:1953–1958
  6. Sanders DB, Bittner RC, Rosenfeld M, Hoffman LR, Redding GJ, Goss CH. Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation. Am J Respir Crit Care Med. 2010;182:627–632
  7. Farrell PM, Rosenstein BJ, White TB, Accurso FJ, Castellani C, Cutting GR, et al. Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report. J Pediatr. 2008;53(Suppl. 1):4–14
  8. Collaco JM, Green DM, Cutting GR, Naughton KM, Mogayzel PJ. Location and duration of treatment of cystic fibrosis respiratory exacerbations do not affect outcomes. Am J Respir Crit Care Med. 2010;182:1137–1143
  9. Denton M, Kerr KG. Microbiological and clinical aspects of infection associated with Stenotrophomonas maltophilia. Clin Microbiol Rev. 1998;11:57–80
  10. San Gabriel P, Zhou J, Tabibi S, Chen Y, Trauzzi M, Saiman L. Antimicrobial susceptibility and synergy studies of Stenotrophomonas maltophilia isolates from patients with cystic fibrosis. Antimicrob Agents Chemother. 2004;48:168–171
  11. Sanders DB, Hoffman LR, Emerson J, Gibson RL, Rosenfeld M, Redding GJ, et al. Return of FEV1 after pulmonary exacerbation in children with cystic fibrosis. Pediatr Pulmonol. 2010;45:127–134
  12. VanDevanter DR, O'Riordan MA, Blumer JL, Konstan MW. Assessing time to pulmonary function benefit following antibiotic treatment of acute cystic fibrosis exacerbations. Respir Res. 2010;11:137
  13. Marshall BC. Pulmonary exacerbations in cystic fibrosis: it's time to be explicit!. Am J Respir Crit Care Med. 2004;169:781–782
  14. Liou TG, Adler FR, Fitzsimmons SC, Cahill BC, Hibbs JR, Marshall BC. Predictive 5-year survivorship model of cystic fibrosis. Am J Epidemiol. 2001;153:345–352
  15. Konstan MW, Morgan WJ, Butler SM, Pasta DJ, Craib ML, Silva SJ, et al. Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis. J Pediatr. 2007;151:134–139
  16. Emerson J, Rosenfeld M, McNamara S, Ramsey B, Gibson RL. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol. 2002;34:91–100
  17. Stevens DA, Moss RB, Kurup VP, Knutsen AP, Greenberger P, Judson MA, et al. Allergic bronchopulmonary aspergillosis in cystic fibrosis—state of the art: Cystic Fibrosis Foundation Consensus Conference. Clin Infect Dis. 2003;37(Suppl. 1):225–264
  18. Sanders DB, Bittner RC, Rosenfeld M, Redding GJ, Goss CH. Pulmonary exacerbations are associated with subsequent FEV1 decline in both adults and children with cystic fibrosis. Pediatr Pulmonol. 2011;46:393–400
  19. Gibson RL, Burns JL, Ramsey BW. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med. 2003;168:918–951
  20. Regelmann WE, Elliott GR, Warwick WJ, Clawson CC. Reduction of sputum Pseudomonas aeruginosa density by antibiotics improves lung function in cystic fibrosis more than do bronchodilators and chest physiotherapy alone. Am Rev Respir Dis. 1990;141:914–921

☆ Supported by the Canadian Cystic Fibrosis Foundation.

☆☆ All of the authors have no conflict of interest to declare.

★ The study was performed at The Hospital for Sick Children, Toronto, Canada.

PII: S1569-1993(11)00131-7

doi: 10.1016/j.jcf.2011.07.008

Journal of Cystic Fibrosis
Volume 11, Issue 1 , Pages 8-13 , January 2012

Article Tools

* Image Usage & Resolution